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Key Points
• Lenalidomide CHOP





AITL patients aged 60
to 80 years.
•DNMT3A mutations
were present in 32% of
patients and appeared
to confer shorter PFS.
Angioimmunoblastic T-cell lymphoma (AITL) is a frequent T-cell lymphoma in the elderly
population that has a poor prognosis when treated with cyclophosphamide, doxorubicin,
vincristine, and prednisone (CHOP) therapy. Lenalidomide, which has been safely
combined with CHOP to treat B-cell lymphoma, has shown efficacy as a single agent in AITL
treatment. We performed a multicentric phase 2 trial combining 25 mg lenalidomide daily
for 14 days per cycle with 8 cycles of CHOP21 in previously untreated AITL patients aged 60
to 80 years. The primary objective was the complete metabolic response (CMR) rate at the
end of treatment. Seventy-eight of the 80 patients enrolled were included in the efficacy and
safety analysis. CMR was achieved in 32 (41%; 95% confidence interval [CI], 30%-52.7%)
patients, which was below the prespecified CMR rate of 55% defined as success in the study.
The 2-year progression-free survival (PFS) was 42.1% (95% CI, 30.9%-52.8%), and the 2-year
overall survival was 59.2% (95% CI, 47.3%-69.3%). The most common toxicities were
hematologic and led to treatment discontinuation in 15% of patients. This large prospective
and uniform series of AITL treatment data was used to perform an integrative analysis of
clinical, pathologic, biologic, and molecular data. TET2, RHOA, DNMT3A, and IDH2
mutationswere present in 78%, 54%, 32%, and 22% of patients, respectively. IDH2mutations
were associated with distinct pathologic and clinical features and DNMT3A was associated
with shorter PFS. In conclusion, the combination of lenalidomide and CHOP did not improve
the CMR in AITL patients. This trial clarified the clinical impact of recurrent mutations in
AITL. This trial was registered at www.clincialtrials.gov as #NCT01553786.
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2021. DOI 10.1182/bloodadvances.2020003081.
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Introduction
Angioimmunoblastic T-cell lymphoma (AITL) and related nodal
peripheral T cells lymphomawith a T follicular helper (TFH) phenotype
(PTCL-TFH) are highly prevalent peripheral T-cell lymphomas
(PTCLs) in Western countries,1-3 preferentially affect older patients,
and are associated with autoimmunity, high-stage disease, and
poor outcome.4 AITL is characterized by a prominent tumor
microenvironment associated with vascular hyperplasia, expan-
sion of follicular dendritic cells, and the presence of plasma cells,
lymphocytes, eosinophils, and large B cells that are frequently
infected by Epstein-Barr virus (EBV).4 Neoplastic cells with a TFH
phenotype5 are present in varying proportions and sometimes
have an abundant clear cytoplasm. The molecular mechanisms
sustaining the transformation of normal TFH cells in AITL and
PTCL-TFH include disruption of the regulation of DNA methylation
and hydroxymethylation by mutations in TET2,6,7 DNMT3A,8,9 and
IDH210 and activation of signaling pathways by RHOA mutation
encoding p.G17V11-13 or mutations affecting T-cell receptor (TCR)
or costimulatory pathways.14 TET2 and DNMT3A mutations occur
frequently in hematopoietic progenitor cells6,8 and are present in
different cell subsets,15,16 suggesting that they may not only have an
effect on neoplastic cells but also on bystander cells. However, these
mutations have been mainly studied in retrospective cohorts, and
whether they affect clinical presentation and outcome is unclear.
Despite an improvement in our understanding of AITL oncogenesis,
there has been little therapeutic progress, and patients with AITL
still have a poor prognosis when treated with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) therapy, making
the development of new treatments an unmet need.
Lenalidomide has a complex mechanism of action, combining
antiproliferative effects on tumor cells, which are mediated by the
inhibition of the protein CEREBLON, antiangiogenic properties, and
an increased immune response.17 The combination of lenalidomide
with rituximab, cyclophosphamide, doxorubicin, vincristine, and pred-
nisone (R-CHOP) chemotherapy in diffuse large B-cell lymphoma18-20
and follicular lymphoma21 has shown an acceptable safety profile
but variable efficacy. Furthermore, lenalidomide has been demon-
strated to have anti-lymphoma efficacy in relapsed-refractory (R/R)
PTCL as a single agent,22-25 especially in AITL.22
Here, we present the results of a phase 2 trial combining
lenalidomide and CHOP in previously untreated AITL patients
aged 60 to 80 years. Taking advantage of this prospective and
homogeneous cohort, we also studied the clinical, pathologic,
biologic, and molecular features of AITL and correlated them to
outcome, aiming to identify predictive factors.
Methods
Study design and participants
The REVlimid in AngioImmunoblastic-T cell Lymphoma (REVAIL)
study was an open-label, single-arm, multicenter, phase 2 clinical
trial. Because the indication of autologous stem cell transplantation
is highly debated in young patients as an upfront AITL treatment, we
focused our trial on elderly patients aged 60 to 80 years who were
eligible to participate in the trial if they had untreated, histologically
proven AITL and a good performance status with an Eastern
Cooperative Oncology Group (ECOG) score 0-2. Patients were
excluded if they had central nervous system involvement; a contra-
indication or hypersensitivity to any of the trial drugs; active
bacterial, viral, or fungal infection, particularly active hepatitis B or
C or HIV-positive serologic tests; impaired renal function (creatinine
clearance , 50 mL/min); impaired liver function (total bilirubin
level . 30 mmol/L, transaminases . 2.5 times the upper normal
limits); poor bone marrow (BM) reserves (as defined by,1.03 109/L
neutrophils or ,100 3 109/L platelets, unless related to the
lymphoma); or any history of other malignancy during the past
5 years.
This study complied with all provisions of the Declaration of Helsinki
and its current amendments and was conducted in accordance
with Good Clinical Practice guidelines. The protocol and consent
forms were approved by an independent research ethics committee
(CPP Ile de France IV). Patients were required to provide written
informed consent before enrollment. The protocol is available
online, and the study has been registered as NCT01553786.
Procedures
Patients received 8 cycles of lenalidomide-CHOP (Len-CHOP)
every 3 weeks. Each cycle of Len-CHOP consisted of 25 mg of oral
lenalidomide on days 1 to 14 in combination with 50 mg/m2
intravenous doxorubicin, 750 mg/m2 intravenous cyclophospha-
mide, and 1.4 mg/m2 intravenous vincristine (up to a maximum dose
of 2 mg) on day 1 and 40 mg/m2 oral prednisone on days 1 to 5. A
reduction in the dose of lenalidomide was mandatory in case of
toxicity, as described in the protocol (supplemental Appendix).
A total of 4 intrathecal injections of methotrexate were administered
during the first 4 cycles for all patients, which was the standard used
to treat aggressive lymphoma when the trial was designed. The
administration of granulocyte colony-stimulating factor was manda-
tory. Patients received prophylaxis against thrombosis by treatment
with low-molecular-weight heparin throughout the study. Antiemet-
ics and supportive care were the standard of care and provided at
the discretion of the treating physician. Adverse events were
evaluated throughout the treatment period and graded according to
the National Cancer Institute Common Terminology Criteria for
Adverse Events, version 3.0. All grade 3 and 4 events and grade 2
infections were recorded in detail. The response was evaluated by
positron emission tomography-computed tomography (PET-CT)
after 8 cycles, which was planned 30 days (maximum 60 days) after
the last intake of lenalidomide treatment using the Lugano criteria26
and was centrally reviewed by 3 investigators (A.S.C., S.B., and
M.M.). In cases of premature withdrawal during the treatment
period, including for progression, the end-of-treatment evaluation
was performed 30 days after the last drug administration or before
the introduction of any new treatment. After treatment completion,
follow-up consisted of clinical examination every 3 months for
2 years, then every 6 months for 3 years, and thereafter once a year.
CT scans were performed every 6 months for 2 years and every year
thereafter. The minimal expected follow-up was 18 months after the
last patient had completed the treatment. The maximum standard-
ized uptake value (SUVmax) and total metabolic tumor volume were
retrospectively determined at baseline using previously described
methods.27
Outcomes
The primary end point of the trial was the complete metabolic
response (CMR) rate at the end of treatment according to the
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Lugano Classification.26 Secondary end points were the complete
response (CR) rate at the end of treatment according to
the International Harmonization Project,28 as assessed by
the site investigator. Progression-free survival (PFS) at 2 years
(2y-PFS) was defined as the time from registration to relapse
for complete responders or disease progression or death from
any cause, and overall survival (OS) was defined as the time from
the date of registration until the date of death as a result of
any cause.
Pathologic review and biologic analysis
Formalin-fixed paraffin-embedded tumor samples were centrally
collected, reviewed, and classified as AITL or PTCL-TFH according
to World Health Organization 2017 classification.29 Extensive
immunochemistry, including the search for TFH markers and
follicular dendritic cell (FDC) antigens, as well as in situ hybridization
with EBV RNA (EBER) probes, were performed and scored as
described in Dobay et al.30 Bone marrow trephine biopsies were
examined locally. Fresh blood samples were centrally collected for
T-lymphocyte immunophenotyping by flow cytometry with anti-CD2,
-CD3, -CD4, -CD5, -CD8, -CD7, -CD10, and -CD26 antibodies,
and T-clonality assessment was performed by polymerase chain
reaction (PCR) denaturing gradient-gel electrophoresis analyses.31
Circulating neoplastic T cells were characterized by an aberrant
immunophenotype (CD4 and CD10 coexpression, CD3 loss or
downregulation of CD3, and/or loss of CD7) or a monoclonal TCR
rearrangement. EBV viral load in plasma was centrally measured
by quantitative PCR using the Qiasymphony extraction platform
(Quiagen) and artus EBV RG PCR Kit. The results are expressed
in international units per mL (IU/mL). DNA was extracted from
formalin-fixed paraffin-embedded tumor samples, and 9 genes
(RHOA, IDH2, STAT3, STAT5B, CD28, TET2, DNMT3A, SET-
D2,and PLCG1) were sequenced on a Ion Personal Genome
Machine (ion PGM; ThermoFisher Scientific) at an expected depth
of 10003, as previously reported.32
Statistical analysis
We anticipated that 60% of patients would achieve a CR with
Len-CHOP and computed the sample size to provide 80% power
at an overall 5% (1-sided) significance level to detect a CMR
improvement from 45% to 60% (null hypothesis, 45%; alternative
hypothesis, 60%), with 45% being an early estimate based on
the results of the previous LYmphoma Study Association (LYSA)
trial Rituximab in AngioImmunoblastic T-cell Lymphoma (RAIL).33
Success of the study was defined as an observed number of
responses statistically significantly higher than the null hypothesis,
meaning that the lower limit of the 90% confidence interval (CI) is
higher than 45%. If 78 patients were analyzed, 43 responding
patients would correspond to 90% CI (0.453-0.648), which is the
lower number of responding patients with 90% CI, excluding 0.45.
This means that 43 of 78 (55%) patients are the prespecified
minimum responses that would be considered a success for this
trial. The sample size calculation was based on Simon’s randomized
phase 2 design. The first-stage analysis was performed after 37
evaluable patients had been included. Because 17 patients
achieved a CR, the trial proceeded to the second stage, and we
planned to recruit 70 evaluable patients for an estimated total of 80
included participants, given the expected dropout rate. Censored
data are presented as Kaplan-Meier plots of time to first event and
summary tables of Kaplan-Meier estimates for criterion rates at fixed
timepoints, with 95% CIs. Patients who received at least 1 dose of
the study treatment were included in the safety analysis, and those
who received at least 1 cycle of treatment were included in the
efficacy analysis.
Correlations between the presence of a mutation and clinical or
pathologic features were studied using logistic regression.
Results
Patients and treatment
In total, 80 patients were enrolled between November 2011
and March 2017 in 23 centers in France and 2 in Belgium. Two
patients did not receive at least 1 dose of treatment (1 because of
withdrawal of consent and 1 because of a rapid change in general
condition) and were excluded from the safety and efficacy analyses,
meaning that 78 patients were included in the efficacy and safety
analysis. Seventy-one patients who received at least 1 dose of
N=80 patients included in the study
2 patients did not receive the first cycle of treatment
   -1 consent withdraw
   -1 rapid general condition degradation
N=78 patients included in the study
N=44 patients completed the study
N= 34 prematurely discontinue the study
           Toxicity of study treatment=12
           Progressive disease=8
           Death = 3
           Patient decision N=4
           Consent withdrawal = 2
           CNS involvement= 2
           Concurrent illness = 2
           Investigator decision =1
N=71 patients with a confirmed
diagnosis of AITL/TFH PTCL
Diagnosis:
Missing =2
T-cells and histiocyte -rich DLBCL=1
Unclassified PTCL=3
Uncertain diagnosis of tumor=1 
Figure 1. Flowchart of the study.
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lenalidomide and 1 cycle of CHOP had a confirmed diagnosis of
AITL (N5 67) or nodal PTCL with a TFH phenotype (N5 4). These
patients were included in the sensitivity analysis and ancillary
studies and are subsequently referred to as the AITL/TFH set
(Figure 1).
The baseline characteristics of the patients are listed in Table 1.
Briefly, the median age was 70 years (interquartile range, 67-73),
and 37.7% of patients had an IPI of 4 to 5, 49.3% had bone marrow
infiltration (BMI), and 42.9% had hypergammaglobulinemia, which
is a typical feature of AITL. Forty-four (55%) patients completed the
study, whereas 34 discontinued the treatment prematurely because
of toxicity (N 5 12), progressive disease (N 5 8), death (N 5 3),
withdrawal of consent (N 5 2), major protocol violation (N 5 2),
concurrent illness (N 5 2), patient decision (N 5 4), or investigator
decision (N 5 1). The median dose intensity received by the
patients was 2275/2800 mg (81%) for lenalidomide, 98% for
doxorubicin, and 97% for cyclophosphamide. The median interval
between cycles was 21 days.
Clinical activity
Forty-five patients received 8 cycles of Len-CHOP. A patient died of
myocardial infarction after the eighth cycle but before the evaluation
by PET-CT, resulting in 44 evaluated patients. Among the evaluated
patients, 43 of 44 patients were evaluated by PET-CT, and CMR
was achieved in 32 (41%; 95% CI: 30%-52.7%) patients and
a partial response in 12 (15.4%), representing an overall response
rate of 56.4%. In addition, 1 patient evaluated by CT presented
a CR on CT, had a normal BM trephine, and was therefore
considered to be in CMR. Thirteen patients (16.7%) had stable or
progressive disease, 3 patients died (4%), and 18 (23%) were not
evaluated, meaning that they were not assessed by PET-CT at the
end of treatment or after a premature withdrawal (Table 2; Figure 1).
The CMR rate was lower than the prespecified CMR of 55% to
meet the primary end point of this study. With a median follow-up of
45 (95%CI: 36-65.9) months, the 2-year PFS was 42.1% (95%CI:
30.9-52.8) and the 2-year OS was 59.2% (95% CI: 47.3-69.3;
Figure 2). Fifteen patients in complete response relapsed during the
follow-up, and the median duration of response was 42.6 (95% CI:
24-not estimable) months. Similar results were observed for the 71
patients with a confirmed diagnosis of AITL/TFH (supplemental
Figure 1).
At the time of the analysis, 41 patients had experienced relapsed
or refractory disease. Thirty-three patients received second-line
chemotherapy, the most frequent being bendamustine in 9
patients and a combination of gemcitabine and oxaliplatin in 7
patients, resulting in a second complete response in only 5
patients. Only 1 patient received second-line autologous stem
cell transplantation.
Forty-two patients died during the follow-up. The cause of death
was lymphoma in 29 (69%) patients, toxicity of the study treatment
in 4 (10%), concurrent illness in 3 (7%), and unknown in 4 (9.5%).
Safety
Neutropenia was the most frequent adverse event, with grade 4
neutropenia occurring in 55 (71%) patients (Table 3). Eighteen
patients (23%) experienced grade 3 or 4 infections. A grade 5
adverse event occurred in 4 patients: 3 patients developed
sepsis, including 2 during the neutropenic phase, and 1 patient
experienced fatal myocardial infarction occurring after the
eighth cycle. Eight patients presented a rash, which was grade





Age median (IQR) 70 (67-73) 70 (67-73)
Sex
Female 41 (53) 38 (53)
Male 37 (47) 33 (47)
B symptoms 44/78 (56) 40/71 (56)
Ann Arbor stage
I-II 5 (6) 5 (7)
III-IV 73 (94) 66 (93)
Number of extranodal sites
0-1 40 (51) 38 (53)
.1 38 (49) 33 (47)
ECOG performance status
0-1 61 (78) 54 (76)
2 17 (22) 17 (24)
Bone marrow involvement 36/73 (49) 32/66 (48)
Hypergammaglobulinemia 30/70 (43) 29/64 (45)
Elevated LDH 42/77 (55) 39/70 (56)
Histology
AITL 67 (94) 67 (86)
Nodal PTCL with TFH phenotype 4 (6) 4 (5)
Other* 7 (9) 0 (0)
IPI
1-3 48 (62) 43 (61)
4-5 29 (38) 27 (39)
PIT
0-2 50 (69) 45 (69)
3-4 22 (31) 20 (31)
SUVmax median (IQR) 11 (7-18) 12 (7-18)
TMTV median (IQR) 433 (127-937) 468 (125-942)
Data n (%) or n/N (%) except as noted.
IPI, International Prognostic Index43; PIT, Prognostic Index for peripheral T-cell lymphoma,
unspecified.44
*Other diagnosis consisted of T cells and histiocyte-rich diffuse large B-cell lymphoma (N
5 1), PTCL that cannot be classified (N 5 3), uncertain diagnosis of tumor (N51), and no
histologic material available for pathologic review (N 5 2).
Table 2. Response rate using the Lugano criteria (N 5 78)
Response assessment n (%)
Overall response rate 44 (56)
Complete metabolic response 32 (41)
Partial response 12 (15)
Stable disease or progressive disease 13 (17)
Death 3 (4)
Not evaluable 18 (23)
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3 in 2 patients. Ten episodes of venous thrombosis were
detected in 8 patients. Constipation was reported in 10 (13%)
patients, including 9 grade 2 and 1 grade 3 constipation, and
peripheral neuropathy was reported in 14 (18%) patients, 2 of
whom were affected by grade 3 neuropathy. Four secondary
primary malignancies were reported, 1 myelodysplastic syndrome,
1 acute myeloid leukemia, 1 marginal zone B-cell lymphoma, and
1 neuroendocrine tumor, which were diagnosed 17, 23, 36, and
16 months after inclusion, respectively.
Pathologic and molecular features
The pathologic features of the 71 confirmed AITL/TFH biopsies are
shown in Figure 3. BMI was diagnosed on the pretherapeutic
staging BM biopsy in 32 of 66 (48%) patients. A significant
circulating clonal T-cell population (ie, representing $10% of the
T-cell compartment, subsequently called a clonal population) was
detected in 28 of 55 (51%) patients, and a phenotypically aberrant
population was detected by flow cytometry in 30 of 53 patients
(57%). This aberrant population, presumed to be circulating tumor
cells, was less than 100 cells/mm3 in 16 of 53 (30%) patients.
There was no correlation between the presence of BMI and the
detection of an abnormal population in the blood (supplemental
Figure 2), suggesting that BM evaluation using BM trephine is still
required in this disease. EBV was detected in the blood in 48 of 59
(81%) patients, with a median of 5812 (interquartile range, 1413-
48480) copies. The detection of the EBV DNA in the plasma did
not correlate with the detection of EBER in the biopsy (P 5 .78;
supplemental Figure 3). The SUVmax was not associated with
a higher percentage of tumor cells estimated in the tumor biopsy by
immunochemistry, but samples with a higher number of EBER-
positive cells (.5 EBER-positive cells by high-power field) showed
a trend toward a higher SUVmax (P 5 .06), suggesting that B cells
from the tumor microenvironment could, at least in part, participate
in the glucose avidity of the AITL lymph nodes (supplemental
Figure 2).
Sixty-three samples were successfully sequenced. As previously
described, TET2 mutations were the most common alteration and
were found in 49 of 63 (78%) patients; multiple mutations were
often detected (28 of 49, 57%). The RHOA mutation encoding
p.G17V was detected in 34 (54%) patients. DNMT3A mutations
were present in 20 (32%) patients, including 6 (9.5%) with a
mutation affecting the R882 residue (DNMT3AR882X). IDH2
mutations, all affecting residue R172, were present in 14 (22%)
patients, and mutations in CD28, PLCG1, STAT3, and STAT5B
were detected in 6, 3, 2, and 1 patients, respectively (Figure 3). As
previously reported, the variant allele frequencies of TET2 and
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Figure 2. Kaplan-Meier curves for PFS and OS. (A) PFS. (B) OS.
Table 3. Relevant adverse events presented by patients and by
highest intensity
Grade 1-2 Grade 3 Grade 4 Grade 5
Hematologic toxicity
Neutropenia 5 (6) 15 (19) 55 (71) 0 (0)
Anemia 27 (34) 26 (33) 3 (3) 0 (0)
Thrombocytopenia 12 (15) 12 (15) 24 (31) 0 (0)
Febrile neutropenia 0 (0) 9 (11) 4 (5) 0 (0)
Infection
Sepsis 1 (1) 5 (6) 6 (8) 4 (5)*
Pneumonia 1 (1) 5 (5) 1 (1) 0 (0)
Upper respiratory tract infection 12 (15) 0 (0) 0 (0) 0 (0)
Digestive tract infection 0 (0) 2 (3) 0 (0) 0 (0)
Urinary tract infection 4 (5) 2 (3) 0 (0) 0 (0)
Other 9 (12) 2 (3) 1 (1) 0 (0)
Nonhematologic adverse events
Fatigue 15 (19) 4 (5) 0 (0) 0 (0)
Nausea/vomiting 18 (23) 4 (5) 0 (0) 0 (0)
Peripheral neuropathy 12 (15) 2 (3) 0 (0) 0 (0)
Rash 7 (9) 2 (3) 0 (0) 0 (0)
Thrombosis 7 (9) 1 (1) 0 (0) 0 (0)
Data are n (%). Hematologic adverse events, infection, and events occurring in more
than 15% of the 78 patients.
*Patient died of septic shock, related to treatment, and had progressive lymphoma.
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consistent with TET2 and DNMT3 being ancestral mutations in this
disease (supplemental Figure 4).
TET2mutations were associated with an age. 65 years and higher
IPI (supplemental Table 1). TET2 and RHOA mutations, known to
be associated with PTCL with a TFH phenotype, were associated
with strong Inducible T-cell costimulator (ICOS) expression (.30%
positive cells). RHOA mutations were associated with significant
FDC expansion (defined as a score $ 2, meaning they had at least
perivascular or perifollicular expansion30). IDH2 mutations, also
associated with FDC expansion, were associated with the
presence of large clear cells with an abundant cytoplasm, which
are a characteristic of a subset of AITL, and these findings were
consistent with a previous report.34 Unexpectedly, IDH2 and
RHOA mutations, which are known to be restricted to neoplastic
T cells,35 were significantly associated with BMI (supplemental
Table 1).
Although most of the mutations did not affect the response rate or
PFS, DNMT3A mutations showed a trend toward a lower rate of
CMR and correlated with significantly shorter PFS (supplemental
Table 2). Notably, none of the patients bearing the frequent
mutation DNMT3AR882X responded to Len-CHOP therapy. Overall,
no single mutation predicted OS, but the 8 patients harboring TET2,
DNMT3A, and IDH2 mutations showed shorter survival than the
others (supplemental Table 1; supplemental Figure 5).
Predictive factors of outcome and prognosis markers
We took advantage of this well-annotated series to identify clinical,
biologic, metabolic imaging, and molecular factors that may predict
the response to treatment or prognosis in AITL (Figure 4).
An IPI score of 3 to 5 was associated with a lower CMR rate and
a shorter OS, confirming the value of this prognostic index in this
disease. Apart from the IPI, a detectable phenotypically aberrant
2 TET2 mutations
1 TET2 mutation























































































Figure 3. Description of molecular, pathologic, biologic, and imaging features of 71 AITL/TFH patients in the REVAIL trial. The section “mutations in tumor”
describes distribution of mutations in TET2, RHOA, DNMT3A IDH2, CD28, PLCG1, STAT3, and STAT5B. Patients represented in dark blue bore at least 2 TET2 mutations,
whereas only 1 TET2 mutation was detected in light blue samples. DNMT3AR882X variants are represented in dark green, whereas samples in light green harbored DNMT3A
mutations altering another residue than R882. Sequencing failure, in gray, was because of the absence of enough material for DNA extraction or the presence of degraded
DNA. In the section “BM/Blood,” BMI represents the presence of bone marrow involvement, as determined locally by the examination of BM trephine. Flow cytometry positivity
means that cells with an aberrant phenotype were detected in blood by flow cytometry before treatment. PCR positive means that a significant (ie, representing at least 10% of
the T-cell population) TCR clonal population was detected by denaturing gradient-gel electrophoresis PCR. EBV blood shows patients with a high level of EBV . 3 log, a low
level of EBV (,3 log), or the absence of detectable EBV replication in blood. “pathological features and IHC” section describes the pathologic features of AITL biopsy. Blue is
used to describe neoplastic cells, whereas the tumor microenvironment is scored in yellow. The percentage of neoplastic T cells was estimated by pathologists after IHC
interpretation: .50% in darker blue cases, 30% to 50% in blue cases, and ,30% in lighter blue cases. Clear cells with a large cytoplasm were detected in cases in dark blue,
absent in cases in white, or unknown in gray. Immunohistochemistry assays for TFH markers (CD10, PD1, CXCL13, BCL6, ICOS) are described in the legend, with score 3
indicating .50% positive tumor cells, score 2 indicating 30% to 50% positive tumor cells, score 1 indicating ,30% positive cells, and score 0 indicating no staining on tumor
cells. FDC distribution was evaluated by CD21 and/or CD23 immunostaining and was assigned a score of 0 when the signal was restricted to germinal centers; 1 in case of
perifollicular expansion; 2 in case of perifollicular and perivascular expansion; or 3 for diffuse expansion. The EBV status in large lymphoid cells was based on counting EBER-
positive large cells and scored as follows: negative, absence of large EBV-positive cells; positive, up to 5 large EBV-positive cells per high power field (hpf); strongly positive,
more than 5 per hpf or sheets or aggregates of large EBV-positive cells. As indicated in the legend, the sections “others” represent IPI at diagnosis (IPI 4-5 vs 1-3), CMR
(CMR vs other response or nonevaluable), and SUVmax and TMTV, both being dichotomized at the median of the cohort.
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population in the blood was associated with a lower CMR rate but
did not affect PFS or OS. More than 1 extranodal site, BMI, albumin
levels inferior to normal, b2 microglobulin . 3.5 g/L, and DNMT3A
mutation were associated with shorter PFS, whereas male sex, low
albumin levels, and b2 microglobulin . 3.5 g/L were associated
with shorter OS. Remarkably, BMI was associated with shorter PFS
and OS, but the detection of an abnormal circulating lymphoid cell
population, which was presumed to be neoplastic cells, by flow
cytometry or PCR, did not highlight the difference between BM and
blood dissemination in TFH-derived lymphoma.
Total metabolic tumor volume (TMTV) was not associated with PFS
or OS in dichotomizing patients, either by the median (433 mm3) or
the previously determined36 threshold of 230 mm3 (supplemental
Figure 6). Given the limited statistical power, multivariate analyses
were not performed in this cohort.
Discussion
Our results do not support the addition of lenalidomide to CHOP in
untreated elderly AITL patients. The primary end point of an increase
in the CMR rate from 45% to 60% was not reached, and the CMR
was 41% (95% CI: 30%-52.7%). Another trial assessing the
combination of lenalidomide with cyclophosphamide, doxorubicin,
vincristine, etoposide, and prednisone (CHOEP) in nodal PTCL
showed a CR rate of 48% and a high rate of early discontinuation,37
consistent with our results. Taken together, these data indicate the
lack of benefit of the addition of lenalidomide to chemotherapy in
the upfront treatment of AITL.
This trial is one of the largest studies dedicated to AITL and TFH
lymphomas and allowed us to prospectively study the mutational
landscape of AITL and its association with clinical features and
outcomes. Patients bearing both TET2 and RHOA mutations
appeared to exhibit high ICOS expression more frequently than
those without these mutations. The expression of RHOAG17V in the
T-cell lineage was recently shown to result in ICOS overexpression
in a mouse model.38 Our observation reinforces the relationship
between ICOS, which may be a critical player in the oncogenesis of
AITL, and the RHOA mutation. DNMT3A mutation was associated
with a trend toward a lower CMR rate and significantly shorter
PFS. Furthermore, no patient carrying the DNMT3AR882X variant
achieved CR. This finding suggests that previous results observed
in acute myeloid leukemia, showing that DNMT3AR882X confers
resistance to anthracyclins,39 by impairing nucleosome eviction and
chromatin remodeling in response to anthracycline treatment, could
translate to AITL. Non–anthracycline-based frontline chemotherapy
might be given to such patients or participation in clinical trials
exploring other novel combinations that could potentially overcome
this resistance.
Predictive factors for survival have been previously investigated. In our
study, TMTV was not predictive of PFS or OS, in contradiction to
previous reports from our group and another.36,40 However, these 2
previous publications included a large proportion of PTCL that was not
otherwise specified and anaplastic large-cell lymphomas, for which the
disease presentation and metabolic volume frequently might differ from
those of AITL, possibly explaining the observed discrepancy.
AITL remains a difficult-to-treat lymphoma, and no significant
therapeutic progress has been made in years. No positive signal
of efficacy was seen in the previous LYSA phase 2 trial RAIL, in
which 27 previously untreated patients with AITL, aged 60 to
80 years, were treated with a combination of rituximab and CHOP
between 2005 and 2008.33 The CR rate was 44%, median PFS
was 16 months, and median OS was 28 months, similar to the
results of the REVAIL trial, for which the CMR rate was 43.6%,
median PFS was 14 months, and median OS was 32 months,
confirming the lack of benefit from the addition of rituximab or
lenalidomide to CHOP in elderly patients with AITL. These results
also emphasize the absence of the improvement in AITL patient
survival during the last few decades and stress the need to develop
alternative therapies to increase the response rate and the duration
of response of AITL patients, including new strategies, such as
maintenance to increase the duration of response of AITL patients.
In this trial, patients with mutations in the 3 epigenetic modifiers
TET2,DNMT3A, and IDH2 had a poor prognosis, with a median OS
of 14 months when treated with CHOP-based therapy. Targeting
the modification of the epigenome is an attractive option in this
disease, which shows a high frequency of mutations that disrupt
epigenetic regulator genes. Indeed, we and others have observed
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Figure 4. Forest plot representing the impact of clinical, biologic, and molecular features on CMR, PFS, and OS. BMI, bone marrow involvement; TMTV, total
metabolic tumor volume; FCM, flow cytometry; PB EBV, EBV viral load measured in peripheral blood . median.
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in refractory relapsed AITL patients.32 The oral form of 5-azacytidine,
CC-486, has been combined with romidepsin in a phase 1 study,41
with promising results and is currently being tested as a single
agent in R/R AITL in an international phase 3 trial (NCT03593018)
or in combination with CHOP therapy in previously untreated
patients (NCT03542266). Interestingly, although our results suggest
the absence of the efficacy of lenalidomide in combination with
chemotherapy, lenalidomide showed promising activity when com-
bined with 5-azacytidine in high-risk myelodysplastic syndrome,42
suggesting that combining lenalidomide and epigenetic-targeting
drugs might be considered for treating AITL.
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Lymphoı̈des, Hôpitaux Universitaires Henri Mondor, 51 Av de Lattre
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